procaine penicillin, gentamicin, amoxicillin — Competitive Intelligence Brief

procaine penicillin, gentamicin, amoxicillin (procaine penicillin, gentamicin, amoxicillin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antibiotic. Area: Infectious diseases.

phase 3 Combination antibiotic Penicillin-binding proteins, 30S ribosomal subunit Infectious diseases Small molecule

Target snapshot

procaine penicillin, gentamicin, amoxicillin (procaine penicillin, gentamicin, amoxicillin) — Aga Khan University. Procaine penicillin is a combination antibiotic that works by inhibiting bacterial cell wall synthesis and protein synthesis, while gentamicin is an aminoglycoside antibiotic that works by inhibiting protein synthesis, and amoxicillin is a beta-lactam antibiotic that works by inhibiting cell wall synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
procaine penicillin, gentamicin, amoxicillin TARGET	procaine penicillin, gentamicin, amoxicillin	Aga Khan University	phase 3	Combination antibiotic	Penicillin-binding proteins, 30S ribosomal subunit
amoxicillin and gentamicin	amoxicillin and gentamicin	Aga Khan University	phase 3	Beta-lactam antibiotic, Aminoglycoside antibiotic	Penicillin-binding proteins, 30S ribosomal subunit
amoxicillin and metronidazole	amoxicillin and metronidazole	University of Campinas, Brazil	marketed	Combination antibiotic (beta-lactam + nitroimidazole)	Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)
levofloxacin; metronidazole	levofloxacin; metronidazole	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Fluoroquinolone + Nitroimidazole combination antibiotic	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole)
Colistin/Polymyxin B + Tigecycline/Eravacycline	Colistin/Polymyxin B + Tigecycline/Eravacycline	National University of Singapore	marketed	Polymyxin + tetracycline combination antibiotic	Bacterial cell membrane (polymyxins) and 30S ribosome (tetracyclines)
Minocycline,Metronidazole	Minocycline,Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic	Bacterial 30S ribosome (minocycline); microbial DNA/RNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antibiotic class)

1. Aga Khan University · 1 drug in this class
2. Shanghai Jiao Tong University School of Medicine · 1 drug in this class